1.90Open1.90Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover2036.74%IV-399.19%PremiumJan 17, 2025Expiry Date4.38Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4760Delta0.3052Gamma0.14Leverage Ratio-0.0710Theta-0.0004Rho-0.06Eff Leverage0.0003Vega
Mersana Therapeutics Stock Discussion
GlobeNewswire· 4 mins ago
Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Friday, 10th January at 6:02 am
CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the U.S. Food and Drug...
No comment yet